Evidence map›Paper›PMID 29992492›Full record

Observational studyJournal of cancer research and clinical oncology2018

Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.

David H Murray, Erin L Symonds, Graeme P Young, Susan Byrne, Philippa Rabbitt, Amitesh Roy, Kathryn Cornthwaite, Christos S Karapetis, Susanne K Pedersen

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  12. Article
  13. Potential value of detection of minimal residual disease in colorectal cancer following radical resection.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

David H MurrayClinical Genomics Pty Ltd, North Ryde, NSW, Australia.
Erin L SymondsFlinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University of South Australia, Bedford Park, SA, 5042, Australia. erin.symonds@sa.gov.au.
Graeme P YoungFlinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University of South Australia, Bedford Park, SA, 5042, Australia.
Susan ByrneFlinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University of South Australia, Bedford Park, SA, 5042, Australia.
Philippa RabbittColorectal Surgery, Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Bedford Park, SA, Australia.
Amitesh RoyDepartment of Oncology, Flinders Medical Centre, Bedford Park, SA, Australia.
Kathryn CornthwaiteFlinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University of South Australia, Bedford Park, SA, 5042, Australia.
Christos S KarapetisDepartment of Oncology, Flinders Medical Centre, Bedford Park, SA, Australia.
Susanne K PedersenClinical Genomics Pty Ltd, North Ryde, NSW, Australia.
Flinders University · AUFlinders Medical Centre · AU

Funding

National Health and Medical Research Council APP1017083National Health and Medical Research Council (AU) APP1006242
6 · The paper itself

Abstract

purposeMethylation in IKZF1 and BCAT1 are common events in colorectal cancer (CRC). They are often detected in blood as circulating tumor DNA (ctDNA) at diagnosis and disappear after surgery in most CRC patients. A prospective study was conducted to determine the relationship between detection of these markers following surgery and risk for residual disease and for recurrence.

methodsctDNA status with methylated BCAT1 and IKZF1 was determined within 12 months of surgical resection of CRC, and was related to presence of or risk for residual disease (margins involved, metastases present or nature of node involvement), and to recurrence-free survival.

resultsBlood was collected from 172 CRC patients after surgery and 28 (16%) were ctDNA positive. Recurrence was diagnosed in 23 of the 138 with clinical follow-up after surgery (median follow-up 23.3 months, IQR 14.3-29.5). Multivariate modeling indicated that features suggestive of residual disease were an independent predictor of post-surgery ctDNA status: cases with any of three features (close resection margins, apical node involved, or distant metastases) were 5.3 times (95% CI 1.5-18.4, p = 0.008) more likely to be ctDNA positive. Multivariate analysis showed that post-surgery ctDNA positivity was independently associated with an increased risk of recurrence (HR 3.8, 1.5-9.5, p = 0.004).

conclusionsCRC cases positive for methylated ctDNA after surgery are at increased risk of residual disease and subsequently recurrence. This could have implications for guiding recommendations for adjuvant therapy and surveillance strategies. Randomized studies are now indicated to determine if monitoring cases with these biomarkers leads to survival benefit.

Indexed as

DNA MethylationAgedAged, 80 and overCirculating Tumor DNAColorectal NeoplasmsDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansIkaros Transcription FactorMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualNeoplasm StagingProspective StudiesCirculating Tumor DNAIkaros Transcription FactorIKZF1 protein, humanlong non-coding RNA BCAT1, humanRNA, Long NoncodingCirculating tumor DNA (ctDNA)Colorectal cancer (CRC)Methylated DNAResidual diseaseSurvival

Identifiers

PMID29992492
PMCPMC11813478
OpenAlexW2842070493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.